Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on 'deeply discounted' CLS

(Sharecast News) - Analysts at Berenberg lowered their target price on British commercial property investor CLS Holdings from 100p to 85p on Friday, but said its current share price was still "deeply discounted". Berenberg said CLS' share price has underperformed the wider UK real estate sector by 20% over the last 12 months, reflecting both ongoing negative sentiment towards offices, as well as pricing in execution risks associated with needing to restore balance sheet strength in a "challenging market".

Yet the German bank said CLS' interim results on 13 August confirmed the progress the company was making against its strategic priorities, which in time will rebase the business to deliver "a more focused portfolio" with higher-quality, faster-growing properties, and deliver future earnings growth.

"Management has entered H2 with cautious optimism, having seen signs of improving market fundamentals. While we understand the market's negative sentiment, we believe the share price reaction is overdone," said Berenberg, which reiterated its 'buy' rating on the stock.

Berenberg added that CLS currently trades at a roughly 73% discount to its estimate of spot net asset values, offering a prospective 7.0% dividend yield.

"Our updated price target implies a circa 60% discount to our trough net tangible asset of 208p. Execution risk remains while there is more deleveraging to do in a tough market, but history suggests successful execution may be rewarding," said the analysts.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.